Wynn Capital LLC Invests $749,000 in Novo Nordisk A/S (NYSE:NVO)

Wynn Capital LLC bought a new position in shares of Novo Nordisk A/S (NYSE:NVO) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 7,245 shares of the company’s stock, valued at approximately $749,000.

A number of other institutional investors have also modified their holdings of NVO. Pacific Center for Financial Services increased its holdings in Novo Nordisk A/S by 100.0% during the third quarter. Pacific Center for Financial Services now owns 270 shares of the company’s stock valued at $25,000 after buying an additional 135 shares during the period. Copeland Capital Management LLC increased its holdings in Novo Nordisk A/S by 100.0% during the third quarter. Copeland Capital Management LLC now owns 282 shares of the company’s stock valued at $26,000 after buying an additional 141 shares during the period. Bell Investment Advisors Inc increased its holdings in Novo Nordisk A/S by 79.9% during the third quarter. Bell Investment Advisors Inc now owns 286 shares of the company’s stock valued at $26,000 after buying an additional 127 shares during the period. CNB Bank purchased a new position in Novo Nordisk A/S during the fourth quarter valued at approximately $26,000. Finally, Citizens National Bank Trust Department increased its holdings in Novo Nordisk A/S by 100.0% during the third quarter. Citizens National Bank Trust Department now owns 300 shares of the company’s stock valued at $27,000 after buying an additional 150 shares during the period. 11.54% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

NVO has been the subject of several recent analyst reports. Cantor Fitzgerald restated an “overweight” rating and issued a $160.00 target price on shares of Novo Nordisk A/S in a research note on Thursday, April 18th. BMO Capital Markets initiated coverage on shares of Novo Nordisk A/S in a research note on Friday, April 12th. They issued an “outperform” rating and a $163.00 target price for the company. Morgan Stanley began coverage on shares of Novo Nordisk A/S in a research note on Tuesday, January 23rd. They issued an “overweight” rating and a $120.00 target price for the company. Finally, UBS Group began coverage on shares of Novo Nordisk A/S in a research note on Tuesday, January 16th. They set a “neutral” rating for the company. Two analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $133.60.

Novo Nordisk A/S Stock Performance

NVO traded down $2.44 on Wednesday, reaching $126.20. The stock had a trading volume of 3,137,636 shares, compared to its average volume of 4,833,989. Novo Nordisk A/S has a 12-month low of $75.56 and a 12-month high of $138.28. The company has a current ratio of 0.82, a quick ratio of 0.64 and a debt-to-equity ratio of 0.19. The business’s 50-day moving average price is $126.66 and its two-hundred day moving average price is $111.54. The company has a market cap of $566.33 billion, a P/E ratio of 46.42, a price-to-earnings-growth ratio of 2.09 and a beta of 0.41.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings data on Wednesday, January 31st. The company reported $0.71 earnings per share for the quarter, beating analysts’ consensus estimates of $0.66 by $0.05. Novo Nordisk A/S had a net margin of 36.03% and a return on equity of 90.36%. The company had revenue of $9.51 billion during the quarter, compared to analysts’ expectations of $9.14 billion. Sell-side analysts forecast that Novo Nordisk A/S will post 3.32 earnings per share for the current year.

Novo Nordisk A/S Increases Dividend

The business also recently announced a Semi-Annual dividend, which was paid on Tuesday, April 2nd. Stockholders of record on Monday, March 25th were paid a dividend of $0.664 per share. The ex-dividend date of this dividend was Friday, March 22nd. This represents a dividend yield of 0.9%. This is a boost from Novo Nordisk A/S’s previous Semi-Annual dividend of $0.22. Novo Nordisk A/S’s payout ratio is currently 49.17%.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.